share_log
Reuters ·  Jan 22 12:30
Elicio Therapeutics: Phase 2 Randomized Study of Eli-002 Fully Enrolled, With Formal Interim Analysis of Disease-Free Survival Expected in H1 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 286

Recommended

Write a comment